Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment

Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02156999

Enrollment

100

Registered

2014-06-05

Start date

2014-06-30

Completion date

2025-12-31

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Brief summary

To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients

Interventions

DEVICEIbandronic acid, vitamin D

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* Osteoporosis

Exclusion criteria

* Kidney, parathyroid, congenital bone metabolic disease

Design outcomes

Primary

Measure	Time frame	Description
Changes of bone mineral density	every 4-6 months	To examine the changes of bone mineral density for the purpose of the effectiveness of the drug

Secondary

Measure	Time frame	Description
Improvement of bone turnover markers	Every 3-6 months	To examine the changes of bone turnover markers for the purpose of the effectiveness of the drug

Countries

Japan

Contacts

Primary ContactYukio Nakamura, MD, PhD

yxn14@aol.jp+81-263-37-2659

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026